BordoniB.MyersT. (2020). A review of the theoretical fascial models: Biotensegrity, fascintegrity, and myofascial chains. Cureus. https://doi.org/10.7759/cureus.7092
2.
DocampoE.ColladoA.EscaramísG.CarbonellJ.RiveraJ.VidalJ.AlegreJ.RabionetR.EstivillX. (2013). Cluster analysis of clinical data identifies fibromyalgia subgroups. PLoS One, 8(9), e74873. https://doi.org/10.1371/journal.pone.0074873
3.
GeH. Y.NieH.MadeleineP.Danneskiold-SamsøeB.Graven-NielsenT.Arendt-NielsenL. (2009). Contribution of the local and referred pain from active myofascial trigger points in fibromyalgia syndrome. Pain, 147(1), 233–240. https://doi.org/10.1016/j.pain.2009.09.019
4.
HauserR. A.LacknerJ. B.Steilen-MatiasD.HarrisD. K. (2016). A systematic review of dextrose prolotherapy for chronic musculoskeletal pain. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 9, CMAMD.S39160. https://doi.org/10.4137/CMAMD.S39160
5.
HongC. Z.HsuehT. C. (1996). Difference in pain relief after trigger point injections in myofascial pain patients with and without fibromyalgia. Archives of Physical Medicine and Rehabilitation, 77(11), 1161–1166. https://doi.org/10.1016/S0003-9993(96)90141-0
ReevesK. D.SitR. W. S.RabagoD. P. (2016). Dextrose prolotherapy: A narrative review of basic science, clinical research, and best treatment recommendations. Physical Medicine and Rehabilitation Clinics of North America, 27(4), 783–823. https://doi.org/10.1016/j.pmr.2016.06.001
8.
StaudR.NagelS.RobinsonM. E.PriceD. D. (2009). Enhanced central pain processing of fibromyalgia patients is maintained by muscle afferent input: A randomized, double-blind, placebo-controlled study. Pain, 145(1), 96–104. https://doi.org/10.1016/j.pain.2009.05.020
9.
ZhouL.LiangH.ChenY.HuK.LiuX. (2025). Dextrose prolotherapy at varying concentrations ameliorates tendon injury via IGF-2R: an integrated study of Mendelian randomization and an animal model. Journal of Orthopaedic Surgery and Research, 20(1). https://doi.org/10.1186/S13018-025-05977-9